GlassScriptPhysician profile
Satish Shah
NPI 1427155191
$5,520.75
in general payments reported to CMS, 2019-2025
25 companies · $52.87 in 2025
The $52.87 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $76.21 · 2021: $238 · 2022: $4,356 · 2023: $262 · 2024: $178 · 2025: $52.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Labcorp Holdings INC. | $4,091.77 | 2022 | |
| Elekta, INC. | $281.48 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $130.83 | 2021-2022 | |
| Array Biopharma INC | $115.68 | 2023-2025 | Lorbrena, Braftovi, Mektovi |
| Varian Medical Systems, INC. | $103.83 | 2019 | |
| Janssen Biotech, INC. | $97.09 | 2020-2023 | Imbruvica, Darzalex |
| Novartis Pharmaceuticals Corporation | $91.28 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.94 | 2019-2024 | |
| Pfizer INC. | $56.29 | 2024 | |
| Apellis Pharmaceuticals, INC. | $54.30 | 2023 | Empaveli |
| Genzyme Corporation | $43.34 | 2021 | |
| Astellas Pharma US INC | $42.93 | 2020 | |
| Merck Sharp & Dohme LLC | $41.28 | 2021-2022 | |
| Abbvie INC. | $39.24 | 2024-2025 | |
| Seagen INC. | $37.43 | 2021-2023 | Adcetris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $24.30 | 2021 | |
| Incyte Corporation | $23.70 | 2023 | Jakafi |
| Biohaven Pharmaceuticals, INC. | $23.53 | 2021 | |
| Alnylam Pharmaceuticals INC. | $22.59 | 2023 | Givlaari |
| Servier Pharmaceuticals LLC | $22.47 | 2022 | |
| Mirati Therapeutics, INC. | $20.10 | 2023 | Krazati |
| Emd Serono, INC. | $20.00 | 2019 | |
| Daiichi Sankyo INC. | $17.77 | 2019 | |
| Kite Pharma, INC. | $17.61 | 2024 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $13.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satish Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.